Mr. Ravi Kiran
Chief Business Officer, KineMed, Inc

Ravi Kiron has 25 years of experience in the pharmaceutical and healthcare industry. and is well versed in all aspects of drug discovery and delivery; pre-clinical and early clinical drug development; bioinformatics and database management; M&A, investment due-diligence, and alliance management.

Dr. Kiron’s prior roles include being the Managing Partner at BioPharm Strategy Advisors and Adjuvant Global Advisors, Consulting & Strategic Advisory firms. Prior to Adjuvant, Dr. Kiron was the COO at LifeTech Innovations (LTI), a BD and Strategic Advisory consulting firm. Dr. Kiron was also cofounder and CBO of C2N Diagnostics, LLC. Dr. Kiron was earlier at Johnson & Johnson/ALZA Corporation, responsible for drug delivery technology & research strategy planning, in- and out-licensing, M&A and intellectual property management. Dr. Kiron also spent 14 years at Pfizer Global R&D in the departments of Strategic Alliances, Project Management and Cardiovascular Drug Discovery. Prior to Pfizer, Dr. Kiron was a biochemistry and medicine faculty member at Cornell University Medical Center in New York.


He holds a BSc in Chemistry and an MSc in Microbiology through colleges in Goa from Bombay University, India. He also earned a PhD in Biochemistry from the Indian Institute of Science in Bangalore, India and an MBA from Rensselaer in Hartford, Connecticut, USA.


BioAsia Secretariat, 204, B-Block, Imperial Apartment, Greenlands circle, Ameerpet, Hyderabad -500016, India
Tel: +91 40 66446477 / 6577 Email: info@bioasia.in